Urologic Health, a medical device company focused on non-invasive urodynamics, announced the closing of an $11 million seed financing round to advance its bladder function monitoring platform. The round was led by an undisclosed strategic investor with participation from Edge Medical Ventures, SHD Partners, Longevity Venture Partners, and other healthcare-focused investors.
The funding will support clinical validation, the company’s FDA 510(k) regulatory pathway, and initial commercialization efforts in the United States.
Urologic Health is developing the niu System, a non-invasive platform designed to provide catheter-free urodynamic testing. The company said the system is intended to convert bladder activity into clinically meaningful diagnostic data without catheterization, enabling routine and repeatable monitoring of bladder function.
Bladder dysfunction conditions such as overactive bladder, urinary retention, incontinence, and benign prostatic hyperplasia affect hundreds of millions of people globally. Traditional diagnostic tools are often invasive and uncomfortable, which can discourage patients from pursuing necessary assessments. Urologic Health said its niu System is designed to address these limitations by delivering comprehensive bladder function data through a non-invasive process.
The company said it has completed early feasibility studies demonstrating that the niu System can capture clinically meaningful bladder activity non-invasively. Proceeds from the financing will also be used to continue product and manufacturing development and establish the company’s headquarters in Jersey City ahead of its planned U.S. market entry.
Urologic Health was co-founded by Adam Yaacov and Dr. Noam Omer. The company was founded and incubated at MEDX Xelerator, now known as EdgeLabs, and operates as part of the Edge Medical Ventures portfolio with operations in the United States and Israel.
The niu System is currently limited to investigational use and has not yet been approved for sale in the United States.
KEY QUOTES:
“Invasive urodynamics remains one of the most significant barriers in modern urological care. While treatment options have evolved considerably, the invasive diagnostic process continues to present challenges for patients. Urologic aims to make bladder function assessment easier for clinicians to perform, painless for patients to undergo, and more informative for longitudinal decision-making.”
Adam Yaacov, Co-founder and CEO, Urologic Health
“Urologic Health was established through our unique venture creation model, which works together with strategic industry partners to identify needs and address them by bringing together talented entrepreneurs to build high-potential medical device companies. By combining exceptional engineering talent in Israel with Edge’s operational support, we are able to help companies like Urologic Health move faster through clinical validation, regulatory execution, and early market entry in the United States.”
Shai Policker, Managing Partner, Edge Medical Ventures and Chairman, Urologic Health Board
